Wilson J Liao

List of Publications by Year
in descending order

168 papers	11,150 citations	53794 45 h-index	33894 99 g-index
173 all docs	173 docs citations	173 times ranked	17073 citing authors

#	Article	IF	Citations
1	A cross-sectional study of ethnoracial representation in pediatric plaque psoriasis clinical trials. Journal of the American Academy of Dermatology, 2022, 86, 442-444.	1.2	1
2	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.7	0
3	TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors. Journal of Psoriasis and Psoriatic Arthritis, 2022, 7, 79-92.	0.7	7
4	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Frontiers in Immunology, 2022, 13, 835760.	4.8	11
5	Multiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Hostâ€'Microbe Associations. JID Innovations, 2022, 2, 100115.	2.4	8
6	Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis. Dermatology and Therapy, 2022, 12, 753-760.	3.0	1
7	Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab. JID Innovations, 2022, 2, 100094.	2.4	8
8	The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. Journal of Investigative Dermatology, 2022, , .	0.7	0
9	A Pilot Study to Assess the Reliability of Digital Image-Based PASI Scores Across Patient Skin Tones and Provider Training Levels. Dermatology and Therapy, 2022, 12, 1685-1695.	3.0	3
10	A review of current phase III clinical trials of plaque psoriasis: underâ€representation of nonwhite participants and need for reform. British Journal of Dermatology, 2021, 184, 348-350.	1.5	14
11	Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 19-26.	0.7	15
12	Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. Journal of Allergy and Clinical Immunology, 2021, 147, 2370-2380.	2.9	77
13	Sleep and the Gut Microbiome in Psoriasis: Clinical Implications for Disease Progression and the Development of Cardiometabolic Comorbidities. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 27-37.	0.7	4
14	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports, 2021, 10, 6-15.	2.1	1
15	Efficacy and safety of tildrakizumab 100Âmg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e526-e528.	2.4	4
16	Immunosuppressants, immunomodulators and COVID-19 vaccines: anticipating patient concerns. Journal of Dermatological Treatment, 2021, , 1-4.	2.2	1
17	Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets and Therapy, 2021, Volume 15, 39-51.	3.2	40
18	Nuclear Receptor Coactivator NCOA3 Regulates UV Radiationâ€"Induced DNA Damage and Melanoma Susceptibility. Cancer Research, 2021, 81, 2956-2969.	0.9	7

#	Article	IF	Citations
19	Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 833-844.	3.0	10
20	Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 769-797.	3.0	23
21	Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatology and Therapy, 2021, 11, 799-831.	3.0	12
22	Large-Scale Imputation of KIR Copy Number and HLA Alleles in North American and European Psoriasis Case-Control Cohorts Reveals Association of Inhibitory KIR2DL2 With Psoriasis. Frontiers in Immunology, 2021, 12, 684326.	4.8	7
23	Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 185-197.	0.7	6
24	Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. Journal of Dermatological Science, 2021, 102, 142-157.	1.9	80
25	Insights from Î³-Secretase: Functional Genetics of Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2021, 141, 1888-1896.	0.7	12
26	The future of personalized medicine in psoriasis. Dermatological Reviews, 2021, 2, 282.	0.5	0
27	Layilin Anchors Regulatory T Cells in Skin. Journal of Immunology, 2021, 207, 1763-1775.	0.8	5
28	Inpatient Management of Psoriasis: A Current Perspective and Update for Clinicians. Current Dermatology Reports, 2021, 10, 205-221.	2.1	1
29	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology, 2021, 141, 2112-2122.e3.	0.7	19
30	Perspectives on the Future Development of Mobile Applications for Dermatology Clinical Research. Dermatology and Therapy, 2021, 11, 1451-1456.	3.0	5
31	Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials. Dermatology and Therapy, 2021, 11, 1497-1520.	3.0	5
32	New Frontiers in Psoriatic Disease Research,ÂPart II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology, 2021, 141, 2328-2337.	0.7	21
33	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology, 2021, 141, 2539-2541.	0.7	0
34	Biologics update: ILâ€23 inhibitors. Dermatological Reviews, 2021, 2, 276.	0.5	0
35	Dupilumab-Induced Facial Flushing After Alcohol Consumption. , 2021, 108, 106-107.		2
36	The Role of IL-17 Cytokines in Psoriasis. ImmunoTargets and Therapy, 2021, Volume 10, 409-418.	5.8	24

#	Article	IF	Citations
37	Genome-Wide Association Study of Ustekinumab Response in Psoriasis. Frontiers in Immunology, 2021, 12, 815121.	4.8	6
38	The Interaction of LILRB2 with HLA-B Is Associated with Psoriasis Susceptibility. Journal of Investigative Dermatology, 2020, 140, 1292-1295.e3.	0.7	6
39	Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. Dermatology and Therapy, 2020, 10, 107-117.	3.0	0
40	Beyond the Booth. Dermatologic Clinics, 2020, 38, 157-163.	1.7	7
41	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Current Rheumatology Reports, 2020, 22, 78.	4.7	10
42	Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 61-67.	0.7	4
43	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome CoronavirusÂ2 (SARS-CoV-2). Dermatology and Therapy, 2020, 10, 881-885.	3.0	12
44	Psoriasis Vulgaris Successfully Treated with Goeckerman Treatment at Home: A Patient and Physicianâ€™s Experience. Dermatology and Therapy, 2020, 10, 329-338.	3.0	1
45	Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing. Dermatology and Therapy, 2020, 10, 815-827.	3.0	6
46	Risk of tuberculosis reactivation during interleukinâ€17 inhibitor therapy for psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1449-1456.	2.4	42
47	Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations. Dermatology and Therapy, 2020, 10, 365-386.	3.0	132
48	Update on Sleep and Pulmonary Comorbidities in Psoriasis. Current Dermatology Reports, 2020, 9, 30-35.	2.1	1
49	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. Dermatology and Therapy, 2020, 10, 339-349.	3.0	37
50	Immunopathogenesis of hidradenitis suppurativa and response to antiâ€“TNF-Î± therapy. JCI Insight, 2020, 5, .	5.0	75
51	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis . Journal of Inflammation Research, 2020, Volume 13, 53-60.	3.5	16
52	Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1. SKIN the Journal of Cutaneous Medicine, 2020, 4, s40.	0.3	1
53	Dupilumab for the treatment of severe photodermatitis. JAAD Case Reports, 2019, 5, 614-616.	0.8	5
54	Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Reports, 2019, 5, 624-626.	0.8	14

#	Article	IF	Citations
55	Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments. American Journal of Clinical Dermatology, 2019, 20, 807-815.	6.7	20
56	Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. American Journal of Clinical Dermatology, 2019, 20, 797-805.	6.7	37
57	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. Dermatology and Therapy, 2019, 9, 407-420.	3.0	17
58	Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Reports, 2019, 5, 928-930.	0.8	20
59	Anti IL-17 in psoriasis. Expert Review of Clinical Immunology, 2019, 15, 1185-1194.	3.0	61
60	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives . Psoriasis: Targets and Therapy, 2019, Volume 9, 97-107.	2.2	16
61	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986565.	2.5	11
62	Acrodermatitis continua of Hallopeau: clinical perspectives . Psoriasis: Targets and Therapy, 2019, Volume 9, 65-72.	2.2	34
63	Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy, 2019, 9, 511-523.	3.0	20
64	Examination of Tar-Induced Verrucous Growths Reveals Absence of Human Papillomavirus. American Journal of Dermatopathology, 2019, 41, 865-867.	0.6	0
65	A review of dupilumab in the treatment of atopic diseases. Human Vaccines and Immunotherapeutics, 2019, 15, 2129-2139.	3.3	53
66	The gut microbiome in psoriasis and psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101494.	3.3	75
67	Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatology, 2019, 155, 118.	4.1	60
68	Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight, 2019, 4, .	5.0	60
69	Bioinformatic applications in psoriasis: genetics, transcriptomics, and microbiomics. Seminars in Cutaneous Medicine and Surgery, 2019, 38, E3-E11.	1.6	5
70	Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. Current Dermatology Reports, 2018, 7, 59-74.	2.1	6
71	Tildrakizumab-asmn: Whatâ€™s in a Name?. American Journal of Clinical Dermatology, 2018, 19, 291-292.	6.7	4
72	Review of the mechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment, 2018, 29, 230-232.	2.2	27

#	Article	IF	Citations
73	Secukinumab in the treatment of psoriasis: patient selection and perspectives. Psoriasis: Targets and Therapy, 2018, Volume 8, 75-82.	2.2	13
74	The TNFRSF members CD27 and OX40 coordinately limit T _H 17 differentiation in regulatory T cells. Science Immunology, 2018, 3, .	11.9	38
75	Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatology and Therapy, 2018, 8, 593-604.	3.0	28
76	Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution. Cell Reports, 2018, 25, 871-883.	6.4	206
77	Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome, 2018, 6, 154.	11.1	190
78	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy, 2018, Volume 8, 49-58.	2.2	9
79	The impact of genital psoriasis on quality of life: a systematic review. Psoriasis: Targets and Therapy, 2018, Volume 8, 41-47.	2.2	38
80	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2018, 3, 65-70.	0.7	2
81	Biologics. Updates in Clinical Dermatology, 2018, , 73-92.	0.1	0
82	Candidate long-range regulatory sites acting on the IL17 pathway genes TRAF3IP2 and IL17RA are associated with psoriasis. Experimental Dermatology, 2018, 27, 1294-1297.	2.9	10
83	RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways. Scientific Reports, 2018, 8, 11368.	3.3	31
84	Treatment of Genital Psoriasis: A Systematic Review. Dermatology and Therapy, 2018, 8, 509-525.	3.0	29
85	A Rapid and Cost-Effective Device for Testing Minimal Erythema Dose. Dermatology and Therapy, 2018, 8, 483-489.	3.0	4
86	Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. Dermatology and Therapy, 2018, 8, 405-423.	3.0	4
87	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation. JAMA Dermatology, 2018, 154, 934.	4.1	112
88	Influence of diet on the gut microbiome and implications for human health. Journal of Translational Medicine, 2017, 15, 73.	4.4	1,714
89	The Role of the Skin and Gut Microbiome in Psoriatic Disease. Current Dermatology Reports, 2017, 6, 94-103.	2.1	99
90	Transcriptional landscape of epithelial and immune cell populations revealed through FACS-seq of healthy human skin. Scientific Reports, 2017, 7, 1343.	3.3	18

#	Article	IF	Citations
91	Skin-infiltrating, interleukin-22â€“producing T cells differentiate pediatric psoriasis from adult psoriasis. Journal of the American Academy of Dermatology, 2017, 77, 417-424.	1.2	37
92	Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey. Dermatology and Therapy, 2017, 7, 227-242.	3.0	65
93	Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation. Cell, 2017, 169, 1119-1129.e11.	28.9	477
94	Ethnicity affects the presenting severity of psoriasis. Journal of the American Academy of Dermatology, 2017, 77, 180-182.	1.2	24
95	Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. Journal of the American Academy of Dermatology, 2017, 77, 177-180.	1.2	31
96	Dietary modifications in atopic dermatitis: patient-reported outcomes. Journal of Dermatological Treatment, 2017, 28, 523-538.	2.2	34
97	Psoriasis risk SNPs and their association with HIV-1 control. Human Immunology, 2017, 78, 179-184.	2.4	10
98	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Reports, 2017, 3, 495-497.	0.8	21
99	A cross-sectional study of psoriasis triggers among different ethno-racial groups. Journal of the American Academy of Dermatology, 2017, 77, 756-758.e1.	1.2	12
100	Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review. Dermatology and Therapy, 2017, 7, 349-364.	3.0	66
101	The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review. Dermatology and Therapy, 2017, 7, 425-446.	3.0	40
102	Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA). JAMA Dermatology, 2017, 153, 106.	4.1	39
103	Tumor necrosis factor-Î± inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. Journal of the American Academy of Dermatology, 2017, 76, 334-341.	1.2	110
104	The metabolomics of psoriatic disease. Psoriasis: Targets and Therapy, 2017, Volume 7, 1-15.	2.2	27
105	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 73-80.	0.7	7
106	Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy, 2016, Volume 6, 93-104.	2.2	52
107	Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics, 2016, 17, 841.	2.8	74
108	A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density. Scientific Reports, 2016, 6, 19877.	3.3	16

#	Article	IF	Citations
109	The Patientâ€™s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. Dermatology and Therapy, 2016, 6, 307-313.	3.0	27
110	The Patientâ€™s Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatology and Therapy, 2016, 6, 333-339.	3.0	10
111	The Patientâ€™s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. Dermatology and Therapy, 2016, 6, 315-324.	3.0	18
112	The Patientâ€™s Guide to Psoriasis Treatment. Part 3: Biologic Injectables. Dermatology and Therapy, 2016, 6, 325-331.	3.0	6
113	The role of IL-17 in vitiligo: A review. Autoimmunity Reviews, 2016, 15, 397-404.	5.8	92
114	Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin. Journal of Investigative Dermatology, 2016, 136, 603-609.	0.7	80
115	Inhibitory KIR3DL1 alleles are associated with psoriasis. British Journal of Dermatology, 2016, 174, 449-451.	1.5	32
116	Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nature Communications, 2015, 6, 6916.	12.8	154
117	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes and Immunity, 2015, 16, 193-198.	4.1	17
118	Antiviral gene expression in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1951-1957.	2.4	32
119	Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases. Genes and Immunity, 2015, 16, 120-126.	4.1	29
120	Genomic imprinting in psoriasis and atopic dermatitis: A review. Journal of Dermatological Science, 2015, 80, 89-93.	1.9	18
121	Memory regulatory T cells reside in human skin. Journal of Clinical Investigation, 2014, 124, 1027-1036.	8.2	294
122	Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes. Cell Reports, 2014, 9, 1228-1234.	6.4	104
123	Genetic Epidemiology of Psoriasis. Current Dermatology Reports, 2014, 3, 61-78.	2.1	74
124	Diet and psoriasis, part I: Impact of weight loss interventions. Journal of the American Academy of Dermatology, 2014, 71, 133-140.	1.2	84
125	Diet and psoriasis, part II: Celiac disease and role of a gluten-free diet. Journal of the American Academy of Dermatology, 2014, 71, 350-358.	1.2	80
126	Diet and psoriasis, part III: Role of nutritional supplements. Journal of the American Academy of Dermatology, 2014, 71, 561-569.	1.2	71

#	Article	IF	Citations
127	Tonsillectomy as a treatment for psoriasis: A review. Journal of Dermatological Treatment, 2014, 25, 482-486.	2.2	47
128	No Evidence for Integrated Viral DNA in the Genome Sequence of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2014, 134, 2055-2057.	0.7	4
129	Biologic therapy in erythrodermic and pustular psoriasis. Journal of Drugs in Dermatology, 2014, 13, 342-54.	0.8	19
130	A pilot study demonstrating a nonâ€invasive method for the measurement of protein turnover in skin disorders: application to psoriasis. Clinical and Translational Medicine, 2013, 2, 12.	4.0	20
131	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
132	Skewed distribution of natural killer cells in psoriasis skin lesions. Experimental Dermatology, 2013, 22, 64-66.	2.9	38
133	Phototherapy in Psoriasis: A Review of Mechanisms of Action. Journal of Cutaneous Medicine and Surgery, 2013, 17, 6-12.	1.2	99
134	Association of Cardiovascular and Metabolic Disease Genes with Psoriasis. Journal of Investigative Dermatology, 2013, 133, 836-839.	0.7	62
135	Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. Journal of Dermatological Treatment, 2013, 24, 2-6.	2.2	22
136	Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. Journal of Leukocyte Biology, 2013, 94, 1051-1059.	3.3	15
137	How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. Journal of Dermatological Treatment, 2013, 24, 13-24.	2.2	28
138	The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset. ISRN Dermatology, 2013, 2013, 1-4.	1.9	9
139	Deletion of the activating <scp>NKG</scp>2C receptor and a functional polymorphism in its ligand <scp>HLA</scp>â€Ł in psoriasis susceptibility. Experimental Dermatology, 2013, 22, 679-681.	2.9	31
140	Genetic interplay betweenHLA-CandMIR148Ain HIV control and Crohn disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20705-20710.	7.1	109
141	Tumor Necrosis Factor-Î± Triad: Psoriasis, Cardiovascular Disease, and Depression. Psoriasis Forum, 2013, 19a, 41-49.	0.1	3
142	CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis. PLoS ONE, 2013, 8, e52144.	2.5	10
143	Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genetics, 2012, 8, e1002514.	3.5	66
144	Protective Effect of Human Endogenous Retrovirus K dUTPase Variants on Psoriasis Susceptibility. Journal of Investigative Dermatology, 2012, 132, 1833-1840.	0.7	22

#	Article	IF	Citations
145	A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin. Journal of Investigative Dermatology, 2012, 132, 583-592.	0.7	138
146	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. American Journal of Human Genetics, 2012, 90, 796-808.	6.2	306
147	A Genetic Risk Score Combining Ten Psoriasis Risk Loci Improves Disease Prediction. PLoS ONE, 2011, 6, e19454.	2.5	84
148	Hydroxyurea for the Treatment of Psoriasis with an Emphasis on HIV-Infected Psoriasis Patients: A Review. Psoriasis Forum, 2011, 17a, 180-187.	0.1	11
149	Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes and Immunity, 2011, 12, 176-182.	4.1	99
150	Temporal Dissection of Tumorigenesis in Primary Cancers. Cancer Discovery, 2011, 1, 137-143.	9.4	240
151	Meta-Analysis Confirms the LCE3C_LCE3B Deletion as a Risk Factor for Psoriasis in Several Ethnic Groups and Finds Interaction with HLA-Cw6. Journal of Investigative Dermatology, 2011, 131, 1105-1109.	0.7	89
152	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	7.1	405
153	Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review. Psoriasis Forum, 2011, 17, 180-187.	0.1	6
154	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Psoriasis Forum, 2010, 16a, 36-42.	0.1	22
155	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16a, 17-25.	0.1	37
156	Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis. Journal of Investigative Dermatology, 2010, 130, 2768-2772.	0.7	65
157	Green technologies for room temperature nucleic acid storage. Current Issues in Molecular Biology, 2010, 12, 135-42.	2.4	32
158	A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis. Practical Dermatology, 2010, 7, 31-35.	0.0	7
159	How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis. Psoriasis Forum, 2010, 16, 36-42.	0.1	9
160	Which Psoriasis Patients Develop Psoriatic Arthritis?. Psoriasis Forum, 2010, 16, 17-25.	0.1	19
161	Further Genetic Evidence for Three Psoriasis-Risk Genes: ADAM33, CDKAL1, and PTPN22. Journal of Investigative Dermatology, 2009, 129, 629-634.	0.7	67
162	Genome-wide scan reveals association of psoriasis with IL-23 and NF-Î²B pathways. Nature Genetics, 2009, 41, 199-204.	21.4	1,229

#	Article	IF	Citations
163	Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nature Genetics, 2009, 41, 211-215.	21.4	482
164	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genetics, 2008, 4, e1000041.	3.5	572
165	Scurvy: A presenting sign of psychosis. Journal of the American Academy of Dermatology, 2007, 57, S8-S10.	1.2	15
166	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. , 0, .		1
167	Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives. Psoriasis: Targets and Therapy, 0, Volume 12, 151-176.	2.2	7
168	Psoriasis and Exercise: A Review. Psoriasis: Targets and Therapy, 0, Volume 12, 189-197.	2.2	4